EQS-News: MetrioPharm AG: First patient dosed in a clinical Phase II trial for MP1032 for the treatment of moderate-to-severe chronic plaque psoriasis
EQS Group-News: MetrioPharm AG / Key word(s): Study/Miscellaneous MetrioPharm AG: First patient dosed in a clinical Phase II trial for MP1032 for the treatment of moderate-to-severe chronic plaque psoriasis 07.03.2018 / 18:29 661563 07.03.2018 ...